Insider Transactions in Q1 2021 at Vertex Pharmaceuticals Inc (VRTX)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 05
2021
|
Joy Liu SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
5,141
-7.64%
|
$1,074,469
$209.99 P/Share
|
|
Mar 01
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
2,782
-5.98%
|
$587,002
$211.8 P/Share
|
|
Feb 26
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,218
-14.9%
|
$470,216
$212.42 P/Share
|
|
Feb 25
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
3,028
-2.13%
|
$644,964
$213.79 P/Share
|
|
Feb 25
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
3,634
-1.4%
|
$774,042
$214.0 P/Share
|
|
Feb 25
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
3,028
-2.31%
|
$644,964
$213.79 P/Share
|
|
Feb 25
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
3,586
-1.69%
|
$767,404
$214.25 P/Share
|
|
Feb 25
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,080
-1.73%
|
$230,040
$213.87 P/Share
|
|
Feb 24
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,416
-6.19%
|
$524,272
$217.57 P/Share
|
|
Feb 24
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,898
-6.08%
|
$628,866
$217.57 P/Share
|
|
Feb 24
2021
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
311
-0.93%
|
$67,487
$217.57 P/Share
|
|
Feb 24
2021
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,898
-4.36%
|
$628,866
$217.57 P/Share
|
|
Feb 24
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,416
-6.66%
|
$524,272
$217.57 P/Share
|
|
Feb 24
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,946
-6.31%
|
$639,282
$217.57 P/Share
|
|
Feb 24
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
864
-5.13%
|
$187,488
$217.57 P/Share
|
|
Feb 24
2021
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,036
-3.19%
|
$224,812
$217.57 P/Share
|
|
Feb 24
2021
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
547
-1.53%
|
$118,699
$217.57 P/Share
|
|
Feb 18
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,825
-4.4%
|
$1,651,075
$211.95 P/Share
|
|
Feb 18
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
7,825
-3.69%
|
$1,651,075
$211.89 P/Share
|
|
Feb 18
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
7,825
-4.68%
|
$1,651,075
$211.98 P/Share
|
|
Feb 18
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
9,264
-4.35%
|
$1,954,704
$211.63 P/Share
|
|
Feb 18
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
4,295
-7.23%
|
$906,245
$211.5 P/Share
|
|
Feb 17
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,240
-11.75%
|
$1,316,640
$211.75 P/Share
|
|
Feb 17
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,240
-10.11%
|
$1,316,640
$211.75 P/Share
|
|
Feb 17
2021
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,080
-3.03%
|
$438,880
$211.75 P/Share
|
|
Feb 17
2021
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
13,970
-21.95%
|
$2,947,670
$211.75 P/Share
|
|
Feb 17
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Payment of exercise price or tax liability
|
Direct |
6,240
-12.39%
|
$1,316,640
$211.75 P/Share
|
|
Feb 17
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
7,613
-11.98%
|
$1,606,343
$211.75 P/Share
|
|
Feb 17
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,740
-11.48%
|
$578,140
$211.75 P/Share
|
|
Feb 17
2021
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,000
-5.8%
|
$422,000
$211.75 P/Share
|
|
Feb 11
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
5,283
-4.56%
|
$1,114,713
$211.04 P/Share
|
|
Feb 11
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Open market or private sale
|
Direct |
5,156
-2.6%
|
$1,087,916
$211.23 P/Share
|
|
Feb 11
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
4,318
-2.66%
|
$911,098
$211.2 P/Share
|
|
Feb 11
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Open market or private sale
|
Direct |
4,460
-2.2%
|
$941,060
$211.21 P/Share
|
|
Feb 11
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Open market or private sale
|
Direct |
1,686
-2.09%
|
$354,060
$210.93 P/Share
|
|
Feb 11
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,498
-2.98%
|
$314,580
$210.89 P/Share
|
|
Feb 10
2021
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,974
-4.85%
|
$636,436
$214.16 P/Share
|
|
Feb 10
2021
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,101
-4.43%
|
$663,614
$214.16 P/Share
|
|
Feb 10
2021
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,367
-6.59%
|
$506,538
$214.16 P/Share
|
|
Feb 10
2021
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
2,962
-4.14%
|
$633,868
$214.16 P/Share
|
|
Feb 10
2021
|
Jeffrey M Leiden Executive Chairman |
SELL
Payment of exercise price or tax liability
|
Direct |
13,954
-17.98%
|
$2,986,156
$214.16 P/Share
|
|
Feb 10
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,563
-4.48%
|
$548,482
$214.16 P/Share
|
|
Feb 10
2021
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,421
-3.44%
|
$518,094
$214.16 P/Share
|
|
Feb 10
2021
|
Bastiano Sanna EVP, Cell & Genetic Therapies |
SELL
Payment of exercise price or tax liability
|
Direct |
1,344
-3.21%
|
$287,616
$214.16 P/Share
|
|
Feb 10
2021
|
Paul M Silva SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
651
-2.5%
|
$139,314
$214.16 P/Share
|
|
Feb 10
2021
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,230
-3.45%
|
$263,220
$214.16 P/Share
|
|
Feb 10
2021
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,365
-6.2%
|
$506,110
$214.16 P/Share
|
|
Feb 05
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
SELL
Open market or private sale
|
Direct |
1,930
-3.26%
|
$414,950
$215.0 P/Share
|
|
Feb 05
2021
|
Michael Parini EVP, Chief Adm, Leg & BD Off |
BUY
Exercise of conversion of derivative security
|
Direct |
1,930
+3.16%
|
$165,980
$86.52 P/Share
|
|
Feb 03
2021
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
32,453
+18.1%
|
-
|